标题
Capmatinib for the treatment of non-small cell lung cancer
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume 19, Issue 8, Pages 659-671
出版商
Informa UK Limited
发表日期
2019-08-01
DOI
10.1080/14737140.2019.1643239
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review
- (2019) Shemana Cassim et al. BMC CANCER
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Feasibility of lung cancer prediction from low-dose CT scan and smoking factors using causal models
- (2019) Vineet K Raghu et al. THORAX
- Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
- (2019) Gillianne G.Y. Lai et al. JOURNAL OF CLINICAL ONCOLOGY
- Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
- (2019) Sabrina Baltschukat et al. CLINICAL CANCER RESEARCH
- DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer
- (2019) Kurtis D. Davies et al. Journal of Thoracic Oncology
- Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
- (2018) D Westover et al. ANNALS OF ONCOLOGY
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
- (2018) Neal I. Lindeman et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET -Rearranged Lung Cancers
- (2018) Alexander Drilon et al. Journal of Thoracic Oncology
- Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib
- (2018) Yubo Wang et al. LUNG CANCER
- Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis
- (2018) Huy Gia Vuong et al. LUNG CANCER
- Third generation EGFR TKIs: current data and future directions
- (2018) Chee-Seng Tan et al. Molecular Cancer
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
- (2018) Kiichiro Ninomiya et al. Scientific Reports
- Symptom Signatures and Diagnostic Timeliness in Cancer Patients: A Review of Current Evidence
- (2018) Minjoung M. Koo et al. NEOPLASIA
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET exon 14 Altered Lung Cancers
- (2018) J K Sabari et al. ANNALS OF ONCOLOGY
- Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.
- (2018) D. Ross Camidge et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
- (2018) S S Ramalingam et al. ANNALS OF ONCOLOGY
- Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
- (2018) Seulki Kim et al. Cancer Research and Treatment
- A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification
- (2017) Eric Angevin et al. EUROPEAN JOURNAL OF CANCER
- Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
- (2017) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- OA 09.03 TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
- (2017) M. Ahn et al. Journal of Thoracic Oncology
- MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
- (2017) Alex Drilon et al. Journal of Thoracic Oncology
- Responses to Crizotinib Can Occur in High-Level MET -Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations
- (2017) Rafael Caparica et al. Journal of Thoracic Oncology
- The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
- (2017) Thanyanan Reungwetwattana et al. LUNG CANCER
- MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC
- (2017) William Sterlacci et al. VIRCHOWS ARCHIV
- Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations
- (2017) Keita Masuzawa et al. Oncotarget
- MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
- (2017) Jung Han Kim et al. Oncotarget
- Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment
- (2017) Benjamin Owusu et al. Cancers
- MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life
- (2016) A. Drilon CLINICAL CANCER RESEARCH
- MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
- (2016) J. H. Tong et al. CLINICAL CANCER RESEARCH
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
- (2016) Mark M. Awad et al. JOURNAL OF CLINICAL ONCOLOGY
- Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations
- (2016) Xuewen Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
- (2016) Sinéad A. Noonan et al. Journal of Thoracic Oncology
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
- (2016) Alexa B. Schrock et al. Journal of Thoracic Oncology
- In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
- (2016) Paul E. Hughes et al. MOLECULAR CANCER THERAPEUTICS
- MET Exon 14 Skipping in Non-Small Cell Lung Cancer
- (2016) Rebecca S. Heist et al. ONCOLOGIST
- Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study
- (2015) F M Walter et al. BRITISH JOURNAL OF CANCER
- A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
- (2015) A. Drilon et al. CLINICAL CANCER RESEARCH
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
- (2015) P. K. Paik et al. Cancer Discovery
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Prognostic Value of MET Gene Copy Number and Protein Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Published Literatures
- (2014) Baoping Guo et al. PLoS One
- MET Gene Copy Number Predicts Worse Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC); A Systematic Review and Meta-Analysis
- (2014) Anastasios Dimou et al. PLoS One
- Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
- (2014) Elizabeth Smyth et al. OncoTargets and Therapy
- Targeting MET Amplification as a New Oncogenic Driver
- (2014) Hisato Kawakami et al. Cancers
- Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
- (2013) R. Katayama et al. CANCER RESEARCH
- Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007
- (2013) Sarah Walters et al. THORAX
- Crizotinib for the Treatment of ALK -Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
- (2012) Sai-Hong Ignatius Ou et al. ONCOLOGIST
- A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
- (2010) Ryoichi Onozato et al. Journal of Thoracic Oncology
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
- (2009) Federico Cappuzzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer
- (2008) Katsuhiro Okuda et al. CANCER SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started